CD274 and neoplasm: The combined positive score (CPS), consisting in the number of PD-L1-positive cells (tumour and immune cells) divided by the total number of viable tumour cells and multiplied by 100, was evaluated in the phase 1b multicohort trial KEYNOTE-028, involving patients with relapsed SCLC who were treated with pembrolizumab.